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Abstract
Inhibition of farnesyltransferase (FT) activity has been associated with in vitro and in vivo anti-
leukemia activity. We report the results of a phase 1 dose escalation study of tipifarnib, an oral FT 
inhibitor, in patients with relapsed, refractory, or newly diagnosed (if over age 70) acute 
myelogenous leukemia (AML), on a week-on, week-off schedule. Forty-four patients were 
enrolled, 2 patients were newly diagnosed, the rest were relapsed or refractory to previous 
treatment, with a median age of 61 (range 33–79). The maximum tolerated dose was determined to 
be 1200 mg given orally twice-daily (bid) on this schedule. Cycle one dose-limiting toxicities 
were hepatic and renal. There were 3 complete remissions seen, 2 at the 1200 mg bid dose and one 
at the 1000 mg bid dose, with minor responses seen at the 1400 mg bid dose level. 
Pharmacokinetic studies performed at doses of 1400 mg bid showed linear behavior with minimal 
accumulation between days 1–5. Tipifarnib administered on a week-on week-off schedule shows 
activity at higher doses, and represents an option for future clinical trials in AML.
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Introduction
Inhibition of farnesyltransferase activity has been associated with activity against leukemias 
in vitro and in vivo. Farnesylation is essential to proper functioning of ras (1), a key protein 
in various signaling pathways. After farnesylation, ras localizes at the plasma membrane, 
where it acts as a molecular switch in response to various tyrosine kinase and other cell 
surface receptors. Initially, ras was identified as a potential target in myeloid malignancies 
due to the frequency of N-ras mutations in acute myelogenous leukemia and 
myelodysplasia. However, clinical trials thus far have shown activity for farnesyltransferase 
inhibitors (FTI) even in the absence of RAS mutation (2), suggesting that interference with 
unmutated ras is itself an effective antineoplastic approach, and/or that other farnesylated 
proteins, such as rhoB or the lamins may also be inhibited (3). As there are over 1000 
farnesylated proteins, it remains unclear which are targeted by FTIs, and which are clinically 
relevant. Inhibition of farnesylation on specific proteins may differ depending on the dosing 
and schedule of the FTI inhibitor.
Tipifarnib (R115777, Zarnestra®) is a methylquinolone analogue that competes with the 
CAAX motif for farnesylation. The initial phase1 trial, R115777-USA-1, conducted at the 
National Cancer Institute, used a 5-day, every 12 hour, dosing regimen with an intra-patient 
and inter-patient dose-escalation scheme (4). Protocol-defined maximum tolerated dose 
(MTD) was not achieved at the highest dose level (1300 mg twice daily for five days).
Tipifarnib was studied in myeloid and lymphoid leukemias by Karp, et al. (2), with a dose 
escalation built upon a 21-day continuous dosing schedule. A 29% overall response rate was 
noted in 34 patients, including a CR at the lowest dose level (100 mg bid). In a follow-up 
phase 2 study, dosing at 600 mg twice daily (bid) using the same 21 day schedule, in older 
patients with previously untreated AML or MDS, CR was observed in 14% of patients, with 
an additional 10% showing partial response (5). A study at M.D. Anderson, for patients with 
MDS, also using the 21-day bid dosing schedule, demonstrated a 30% response rate in 20 
patients (6). Their MTD was 400 mg bid; above that dose there were several dose limiting 
toxicities including headache, fatigue, confusion, and vision changes.
It is conceivable that altering the dosing schedule so that tipifarnib is given in a week-on, 
week-off schedule may allow tolerance of administration at higher dose. In a California 
Cancer Consortium solid tumor phase 1 study of week-on, week-off dosing, a DLT of grade 
3 fatigue occurred at the 900 mg bid dose level; no other significant grade 3 toxicities were 
noted (7). In hematologic malignancies, a trial of tipifarnib given on a week-on, week-off 
schedule in patients with high grade myelodysplastic syndrome showed reasonable 
tolerability and responses at different dose levels. Importantly, correlative studies performed 
during this trial and others, have demonstrated farnesyl transferase inhibition for seven days 
after administration of tipifarnib (6–8), suggesting that this alternate-week dosing schedule 
is mechanistically appropriate , and that dose escalation on this schedule might enhance the 
activity of tipifarnib in relapsed, refractory AML.
Thus, we propose a study of this dose escalation regimen in acute myeloid malignancies. 
Pharmacokinetic studies were done to determine the effect of dose on blood levels. Should 
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this regimen be equally effective as conventional-dose tipifarnib monotherapy, but with 
better tolerability and advantageous pKs, it could serve as a platform for combination with 
other agents and chemotherapies.
PATIENTS AND METHODS
Patient Selection
Eligible patients were age 18 or over with acute myeloid leukemia (AML) including: 
relapsed or refractory disease after one to three prior induction regimens (not counting 
consolidation therapies while in CR, such as autologous transplant), newly diagnosed 
disease in patients up to age-70 with poor risk features (unfavorable cytogenetics or findings 
suggestive of prior myelodysplasia) not fit for standard induction therapy, and newly 
diagnosed AML patients age 70 – 75 not fit for standard therapy (without history of prior 
MDS). Patients with acute promyelocytic leukemia of the M3 subtype were excluded. Bone 
marrow and peripheral blood studies were required for confirmation of diagnosis. Patients 
who had been treated with prior autologous transplant, were eligible, and patients post 
allogeneic transplant were allowed in the expansion cohort as long as there was no active 
graft versus host disease or infectious disease related to transplant. A minimum of 4 weeks 
must have elapsed since completion of prior chemotherapy in order to be eligible. Standard 
end organ function criteria were applied, such as serum bilirubin ≤2.0 mg/dl, SGOT and 
SGPT ≤2.5 times the institutional upper limits of normal and excluding patients with a 
pretreatment calculated creatinine clearance (absolute value) of less than 60 ml/minute or 
serum creatinine of < 1.5 × upper limit of normal. There were no minimum hematological 
parameter requirements prior to enrollment, as patients with AML and MDS are understood 
to have low ANC and platelet counts when the disease is active. However, patients with 
WBC greater than 30,000 received hydroxyurea to reduce WBC to below 30,000 at which 
point they were able to commence therapy. Signed informed consent was obtained for all 
study participants and registered by the Data Coordinating Center at City of Hope. Protocol 
and consent forms were approved by the institutional review boards of the participating 
centers.
Treatment Plan
Oral tipifarnib was administered twice daily on days 1–7 and days 15–21 of each 28-day 
cycle. The planned dosing levels are presented in Table 1. Patients received a minimum of 
one treatment cycle, with no pre-defined maximum number of cycles. Patients were 
permitted to stay on study as long as there were no unacceptable toxicities. Intra-patient dose 
escalation was permitted (not beyond the highest dose tested) if CR was not reached in the 
first cycle and there was no significant toxicity. At the higher dose levels, intravenous 
hydration was frequently given with the morning tipifarnib dose. For subjects with rapidly 
rising white blood cell counts after week 1 or 3 of any cycle, hydroxyurea was permitted on 
the intervening week until 24 hours prior to restarting the next dose of tipifarnib. Allopurinol 
was started 24 hours before the first dose of tipifarnib and continued until at least day 22 of 
the first cycle.
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Evaluation of response
Bone marrow aspiration and biopsies were performed as part of the on-study evaluation 
within two weeks prior to starting therapy. Patients were seen a minimum of once weekly 
while on study, with peripheral blood counts and chemistry monitored at least once weekly. 
Bone marrow studies were repeated between days 26 to 28 of each cycle. Clinical responses 
were measured according to International Working Group criteria (9).
Study Design
Patients were enrolled in cohorts of 3, as per standard 3+3 phase 1 study design. Patients 
completed study diaries which were reviewed as part of the toxicity assessment at each 
clinic visit. Adverse events (AEs) were graded using the NCI common toxicity criteria 
(CTCAE) version 3.0. Dose limiting toxicities (DLT) were defined as any grade 2 to 4 non-
hematologic toxicity possibly related to study drug, except for nausea, vomiting and diarrhea 
controllable by routine palliation, any electrolyte disturbance corrected with 
supplementation, or any grade 4 hematologic toxicity in the absence of circulating blasts not 
reversible to grade 3 or less, by 21 days after the end of a cycle. In the presence of residual 
leukemia seen upon aspiration, neutropenia and thrombocytopenia did not count as DLT. 
Dose escalation proceeded if none of the 3 patients in the cohort had a first cycle DLT. If 
one of the three patients in a cohort experienced a DLT, three more patients were accrued at 
that dose level. In the event that a second patient experienced a DLT, that is, 2 or more out 
of 6 patients, then patients were accrued to the next lower dose level. The maximally 
tolerated dose (MTD) was defined as that at which no more than one patient out of six 
experienced a DLT during the first cycle of treatment. Intra-patient dose escalation to 
highest dose open for accrual was allowed if CR was not reached in the first cycle. If PR or 
clinical improvement was not reached after 6 cycles, patients were categorized as treatment 
failure and removed from the study.
Pharmacokinetic studies
Venous blood samples were collected in heparinized tubes at the following times during the 
first cycle: prior to the dose on Day 1, and then at 0.5, 1, 2, 3, 5, 8 and 12 hours post dosing, 
and immediately before the dose on Day 5, and then at 0.5, 1, 2, 3, 5, 8 and 12 hours post 
dosing. Blood was centrifuged for 10 minutes at 1000 × g within 2 hours after collection for 
separation of plasma, and the resulting plasma samples were stored frozen at < -20°C until 
batch analysis. Plasma concentrations of tipifarnib were determined using a previously 
described validated LCMS/MS assay (10).
Individual plasma concentration-time data were analyzed using standard non-compartmental 
methods and the following pharmacokinetic parameters of tipifanib were determined for 
each patient around doses on Days 1 and 5: peak plasma concentration (Cmax), time to reach 
the peak plasma concentration (Tmax), area under the plasma concentration-time curve from 
0 to 12 hours post-dosing (AUC12h)., and the trough plasma concentration (Cmin). In 
addition, the accumulation index was determined by dividing the AUC12h on Day 5 by the 
AUC12h determined on Day 1.
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Results
A total of 44 eligible patients with AML were enrolled in the study. Demographic data are 
listed in Table 1. Median age was 61 (range 33–79). Two patients were newly diagnosed; 
the remaining 42 had relapsed or failed prior therapy, including 5 patients with prior 
autologous transplant and 2 patients with prior allogeneic transplant.
Toxicity
At the 400 mg bid dose level, a grade 5 hepatorenal failure occurred, potentially related to 
the study drug. There were no additional DLTs, and no DLTs at 600 mg bid, 800 mg bid or 
1000 mg bid. At the 1200 mg bid dose level, a grade 3 elevation of the creatinine was seen 
in one patient out of 6 treated. At the 1400 mg bid dose level, in an expanded cohort during 
dose de-escalation one patient experienced a grade 4 hypotension and a rising grade 2 
creatinine that were dose limiting, and a second patient had a rising grade 2 creatinine in 
cycle 1, where treatment was terminated before it reached a grade 3 and was therefore 
considered dose limiting. At the 1600 mg dose level, a grade 3 LFT and a rising grade 2 
creatinine, were dose limiting, and in a second patient, a rapidly rising creatinine was seen 
and the drug stopped before grade 3 was reached. As result, the 1200 mg bid dose was 
established as the maximum tolerated dose (MTD) and an additional 7 patients were treated 
at the MTD. In the total of 13 patients that were treated at the 1200 mg bid dose, there were 
no grade 4 or 5 toxicities. Grade 2 and 3 toxicities are listed in Table 2: there was one grade 
3 creatinine DLT and grade 2 toxicities included hyperglycemia, fatigue, alopecia, 
hyperkalemia, mouth sores, shortness of breath, dizziness, nausea, vomiting, ataxia, 
abdominal pain, headache, and dehydration. For this reason, at the higher doses, tipifarnib 
was administered along with daily IV hydration in most patients. Assessing potential 
hematologic toxicities is challenging in AML studies due to the underlying disease, 
however, among the 3 patients who achieved CR, one patient developed pancytopenia 
resulting in an episode of febrile neutropenia upon subsequent cycles of drug.
Clinical Activity
The number of patients, DLTs and responses for each individual tipifarnib dose are detailed 
in Table 3. One patient at the 1000 mg oral bid dose, who had relapsed after autologous stem 
cell transplant, achieved complete remission (CR) after one cycle, and was taken to 
allogeneic stem cell transplant, and remains in remission for over five years. There were two 
CRs achieved at the 1200 mg bid dose: One patient with relapsed disease after standard 7-
day cytarabine/ 3-day daunorubicin induction and one cycle of consolidation, entered CR 
and remained on study for 17 months until relapse; a second patient at the 1200 mg dose 
level, who had relapsed after first remission, and was resistant to second induction, achieved 
a CR that lasted one month. Also at the 1200 mg dose level, a third patient patient dropped 
from 50% to 7% marrow blasts after 3 cycles. At the 800 mg bid dose a patient’s marrow 
blasts decreased from 36% to 10% over 3 cycles, and at the 1400 mg bid dose bone marrow 
blasts were decreased by 50% or more in two patients.
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Pharmacokinetics
First-dose tipifarnib pharmacokinetic data are available for 10 subjects (Table 4) and 5th 
dose data for a total of 9 subjects (Table 5). Three subjects received doses of 1400 mg and 7 
received 1200 mg bid. The median Cmax after the 1st dose on Day 1 was 3920 µg/L and 906 
µg/L in subjects receiving 1400 mg and 1200 mg, respectively. The median Cmax after the 
dose on Day 5 was 2630 µg/L in subjects receiving 1400 mg and 1210 µg/L at the 1200 mg 
dose level. The median Cmin after the 1st dose was 237 µg/L and 166 µg/L in subjects 
receiving 1400 mg and 1200 mg, while the median Cmin after Day 5 was 476 µg/L and 166 
µg/L, respectively. The median AUC12h after the 1st dose was 13,835 hr·µg/L and 4744 
hr·µg/L in subjects receiving 1400 mg and 1200 mg, while the median AUC12h after the 
dose on Day 5 was 17,148 hr·µg/L and 7366 hr·µg/L. The median AUC12h for two patients 
with decreased blasts was 16295 hr·µg/L and 13221 hr·µg/L on days 1 and 5 respectively, 
while for the remaining patients, the median AUC12h was 7576 hr·µg/L and 4325 hr·µg/L on 
days 1 and 5 respectively. Similarly, median Cmax for these two patients was 2442.5·µg/L 
and 2550 µg/L on days 1 and 5, while median Cmax for the remaining patients was 1290 
µg/L and 881 µg/L on days 1 and 5 respectively. These differences were not statistically 
significant. The median accumulation index in subjects receiving doses of 1400 mg and 
1200 mg daily were 1.17 and 1.2, respectively.
Discussion
Tipifarnib is a methylquinolone analogue that competes with the CAAX motif for 
farnesylation, leading to competitive inhibition of the enzyme farnesyltransferase, which is 
critical to the function of multiple proteins involved in essential pathways for cell survival. 
While initially developed as an agent targeting ras, it appears that tipifarnib may act on 
multiple pathways, and it is possible that its effects on other farnesylated proteins might be 
enhanced if higher doses of the drug could be delivered in a safe manner. For this reason we 
studied escalating doses of tipifarnib in a week-on week-off schedule, which maintains the 
molecular activity of the drug while potentially decreasing toxicity.
In this phase 1 study, consisting almost entirely of patients with relapsed disease, at the 1000 
mg and 1200 mg BID dosing levels, we saw 3 CRs, two of which were of long duration, one 
lasting 17 months and one that enabled the patient to undergo allogeneic stem cell 
transplant; this patient remains disease free for over 5 years. These three patients all had 
relapsed disease and cytogenetic abnormalities (trisomy 21, −7, del20). No formal responses 
were seen among patients treated in the lower dose levels at this schedule.
Tipifarnib pharmacokinetics have been extensively studied at lower doses (13–15), however, 
relatively few data have been reported for doses above 1000 mg. Karp et al. (2) presented 
data for three subjects receiving 1200 mg and Zujewski et al. (4) reported data for 3 subjects 
given doses of 1300 mg. The results presented here are in general agreement with the earlier 
studies, and taken together, the data suggest that the pharmacokinetic behavior of tipifarnib 
is linear up to doses as high as 1400 mg bid. We have also confirmed that relatively modest 
tipifarnib accumulation occurs between days 1 and 5, even at these higher doses. While the 
pharmacokinetic sampling did not include the two patients with complete responses at 1200 
mg, there was a 2–3 fold higher median AUC and Cmax (on both day 1 and day 5) observed 
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in the two patients with decreased blasts assayed when compared to the median of the non-
responders. The current data also indicate a significant degree of both inter- and intra-patient 
variability in tipifarnib pharmacokinetics. The potential sources of such variability, as well 
as its clinical impact, need to be further elucidated.
Although the expansion group is too small (7 patients) to cause concern, it is interesting that 
no complete responses were seen in this group. However, these were the last patients 
accrued to the study, raising the theoretical possibility that resistance to tipifarnib could be 
correlated with prior exposure to hypomethylating agents, which had recently entered 
standard clinical use. This hypothesis should be examined in a larger study in light of known 
resistance mechanisms to 5-aza-2'-deoxycytidine (16) and tipifarnib (17).
Tipifarnib is an agent with clear activity in leukemia; however, it is increasingly clear that 
this activity is limited to disease with certain characteristics, best typified thus far by the 
correlation with the RASGRP1/APTX ratio as determined by gene signature analysis. Our 
study suggests that clinical studies designed to study the role of tipifarnib in these 
populations should consider higher doses on a week-on, week-off schedule.
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Table 1
Patient Characteristics
Patient Characteristics
Number
(percent)
Total patients 44(100)
Age in years (median) 61
     Age range 33–79
     Age < 65 years 24 (55)
Sex
     Male 24 (55)
     Female 20 (45)
Race/ethnicity
     Caucasian 34 (77)
     Hispanic 6(14)
     Asian 4(9)
Median time from diagnosis, months 9.6
Karnofsky performance status (KPS)
     100 11 (25)
     90 17(39)
     80 11 (25)
     70 4(9)
     60 1 (2)
Relapsed / refractory disease 41(93)
Prior hematopoietic cell transplant 7(16)
     Autologous 5(11)
     Allogeneic 2(5)
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Table 2
Toxicity grades 2 and above attributable to treatment at 1200 mg bid dose (excluding hematologictoxicities 
and infection)
Toxicity
Course 1 Subsequent
Grade 2 Grade 3 Grade 2 Grade 3
ALT, SGPT 2 1
Anorexia 2 1
AST, SGOT 1
Ataxia 1
Bilirubin 2 1
Constipation 1
Creatinine 2 1 3
Dehydration 1
Fatigue 3 2
Febrile neutropenia 1
Hyperglycemia 2
Hypoalbuminemia 2 2
Nausea 1 1 2
Rash / desquamination 1
Restless leg syndrome 1
Syncope (fainting) 1
Vomiting 2 2
Weight loss 1
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